



March 31, 2025

Company name Ezaki Glico Co., Ltd.
Representative Katsuhisa Ezaki, Chairman
Securities code: 2206 (Listed stock exchange: Tokyo Stock Exchange)
Contact person Shinichi Takahashi, Senior Corporate Officer, IR
Contact number: (81)-6-6477-8167

Notice Concerning Establishment of a Special Purpose Company (SPC)

The Company hereby announces that, at a meeting of its Board of Directors held today, it resolved to establish and invest in a special purpose company (SPC) with the aim of making global growth investment in the future. As the amount of the investment in the SPC will be equivalent to 10% or more of the Company's share capital, the SPC will be a specified subsidiary of the Company.

1. Background Behind and Objective of the Establishment of the Special Purpose Company (SPC)

The Company set out the goal of "Contribute to the Wellbeing of one billion people globally" in its Mid-Term Management Plan announced on February 13. To achieve this goal, the Company will establish Glico Europe B.V. as a holding company in the Kingdom of the Netherlands with the aim of exploring opportunities for business and investment in Europe in the future.

The Company will continue to focus on expanding its business to new areas and promote growth globally in order to realize its Purpose of "Healthier days, Wellbeing for life."

2. Outline of the SPC

| | | |
|--------------------------------|---|---|
| (1) Name | Glico Europe B.V. | |
| (2) Location | The Kingdom of the Netherlands | |
| (3) Representative | Tetsuya Kuwayama, President and Representative Director | |
| (4) Objective of Establishment | Holding company | |
| (5) Capitalization | 25 million euros (planned) | |
| (6) Date of Establishment | April 2025 (planned) | |
| (7) Relationship between the | Capital Relationship | To be established as a wholly-owned subsidiary of the Company |

| | | |
|------------------------------------|----------------------------|--|
| Company and the SPC | Personnel Relationship | One Corporate Officer of the Company to be appointed as representative |
| | Business Relationship | Not applicable |
| (8) Investors and Investment Ratio | Ezaki Glico Co., Ltd. 100% | |

3. Timetable for Investment

Date of resolution at the meeting of the Board of Directors: March 31, 2025

Planned date of investment: Late April 2025 (planned)

4. Impact on Earnings

The impact of the investment on the Company's consolidated earnings for the fiscal year ending December 31, 2025 will be minor.